CliffBio
small molecule

NUCYNTA ER

TAPENTADOL HYDROCHLORIDE

Loss of exclusivityMarch 2029latest FDA-listed patent expiry
CompanyCollegium Pharmaceutical →View the full company profile on CliffBio

Drug detail

Brand nameNUCYNTA ER
Active ingredientTAPENTADOL HYDROCHLORIDE
StrengthEQ 200MG BASE
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2011
Marketing statusRX

Listed patents

PatentExpiresType
8536130*PEDMarch 2029—
11344512*PEDOctober 2028—
8536130September 2028use U-1276
11344512April 2028use U-3391

More from Collegium Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NUCYNTA ER patent cliff — loss of exclusivity March 2029 | CliffBio